The Case For Letting Biosimilars Compete | Health Affairs

As policy makers try to address unsustainable prices for biologic drugs, concerns about the fledgling US market for biosimilars have come to the forefront. Some experts have even suggested abandoning biosimilars in favor of more heavy-handed mechanisms to lower the prices of biologics. We agree that there are unique barriers to biosimilar competition. Giving up on the biosimilars market…

Read the full article here

Related Articles